ONCOGENEX PHARMACEUTICALS INC | 7,779 Euro | -0,216 -2,70 % | |
| WKN: A0Q8G8 ISIN: US68230A1060 Ticker-Symbol: SP4A | Frankfurt | 23.05.13 | 08:04 Uhr |
Branche PharmaAktienmarkt Sonstige |
|
| Zeit | Aktuelle Nachrichten
Sprache: | Leser | Medien | |
|---|---|---|---|---|
| 13:16 | OncoGenex Plans Cedar Clinical Trial Evaluating OGX-427 in Combination with Chemotherapy in Advanced Squamous Cell Lung Cancer | - | Benzinga.com | |
| 12:40 | OncoGenex Announces Plans for the Initiation of the Cedar™ Clinical Trial Evaluating OGX-427 in Combination with Chemotherapy in Advanced Squamous Cell Lung Cancer | - | CNX Marketlink | |
| 12:32 | OncoGenex Announces Plans for the Initiation of the Cedar' Clinical Trial Evaluating OGX-427 in Combination with Chemotherapy in Advanced Squamous Cell Lung Cancer | 34 | PR Newswire | |
| BOTHELL, Wash.and VANCOUVER, British Columbia, May 23, 2013 /PRNewswire/ --OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced plans for the initiation of the Cedar' clinical trial, an... Mehr lesen zu: OncoGenex Announces Plans for the Initiation of the Cedar' Clinical Trial Evaluating OGX-427 in Combination with Chemotherapy in Advanced Squamous Cell Lung Cancer | ||||
| 22.05. | OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting | 25 | PR Newswire | |
| BOTHELL, Wash. and VANCOUVER, British Columbia, May 22, 2013 /PRNewswire/ --OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), a leader in the development of novel therapeutics to target mechanisms of... Mehr lesen zu: OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting | ||||
| 03.05. | OncoGenex Pharmaceuticals' CEO Discusses Q1 2013 Results - Earnings Call Transcript | - | Seeking Alpha | |
| 02.05. | OncoGenex Pharmaceuticals Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013 | - | Benzinga.com | |
| 02.05. | OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013 | 16 | PR Newswire | |
| BOTHELL, Wash. and VANCOUVER, British Columbia, May 2, 2013 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided an overview of clinical development activities for its two... Mehr lesen zu: OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013 | ||||
| 01.05. | OncoGenex to Initiate Rainier Clinical Trial Evaluating OGX-427 with ABRAXANE plus Gemcitabine | 1 | Benzinga.com | |
| 01.05. | OncoGenex (OGXI) to Initiate OGX-427 Phase 2 in Combo with ABRAXANE | - | StreetInsider.com | |
| 01.05. | OncoGenex Announces Plans for the Initiation of the Rainier™ Clinical Trial Evaluating OGX-427 in Combination with ABRAXANE® plus Gemcitabine in Patients with Metastatic Pancreatic Cancer | - | CNX Marketlink | |
| 01.05. | OncoGenex Announces Plans for the Initiation of the Rainier' Clinical Trial Evaluating OGX-427 in Combination with ABRAXANE plus Gemcitabine in Patients with Metastatic Pancreatic Cancer | 59 | PR Newswire | |
| BOTHELL, Wash. and VANCOUVER, British Columbia, May 1, 2013 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced plans for the initiation of the Rainier' trial, an investigator-sponsored... Mehr lesen zu: OncoGenex Announces Plans for the Initiation of the Rainier' Clinical Trial Evaluating OGX-427 in Combination with ABRAXANE plus Gemcitabine in Patients with Metastatic Pancreatic Cancer | ||||
| 30.04. | OncoGenex Announces that the Borealis-2™ Clinical Trial of OGX-427 in Previously Treated Metastatic Bladder Cancer is now Open for Enrollment | - | CNX Marketlink | |
| 30.04. | OncoGenex Announces that the Borealis-2' Clinical Trial of OGX-427 in Previously Treated Metastatic Bladder Cancer is now Open for Enrollment | 27 | PR Newswire | |
| BOTHELL, Wash. and VANCOUVER, British Columbia, April 30, 2013 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced initiation of the Borealis-2' clinical trial, an investigator-sponsored... Mehr lesen zu: OncoGenex Announces that the Borealis-2' Clinical Trial of OGX-427 in Previously Treated Metastatic Bladder Cancer is now Open for Enrollment | ||||
| 25.04. | OncoGenex to Webcast Discussion of Clinical Development Program and First Quarter 2013 Financial Results on May 2, 2013 | 16 | PR Newswire | |
| BOTHELL, WA and VANCOUVER, BC, April 25, 2013 /PRNewswire/ - OncoGenex
Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's
first quarter 2013 financial results will be released... Mehr lesen zu: OncoGenex to Webcast Discussion of Clinical Development Program and First Quarter 2013 Financial Results on May 2, 2013 | ||||
| 23.04. | OncoGenex Pharmaceuticals to Present at Upcoming Investor Conference | 22 | PR Newswire | |
| BOTHELL, WA and VANCOUVER, BC, April 23, 2013 /PRNewswire/ - OncoGenex
Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Scott
Cormack, President and Chief Executive Officer, will provide... Mehr lesen zu: OncoGenex Pharmaceuticals to Present at Upcoming Investor Conference | ||||
| 12.04. | OncoGenex' OGX-427 Progresses | 2 | Zacks | |
| 12.04. | OncoGenex: A Cancer Biotech Worth Betting On | 2 | Seeking Alpha | |
| 12.04. | OncoGenex to begin Spruce clinical trial to evaluate lung cancer agent | - | Pharma Bus Review | |
| 11.04. | OncoGenex Announces Plans for the Initiation of the Spruce™ Clinical Trial Evaluating OGX-427 in Combination with Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer | 1 | CNX Marketlink | |
| 11.04. | OncoGenex Announces Plans for the Initiation of the Spruce' Clinical Trial Evaluating OGX-427 in Combination with Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer | 69 | PR Newswire | |
| BOTHELL, Wash. and VANCOUVER, British Columbia, April 11, 2013 /PRNewswire/ --OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced plans for the initiation of the Spruce clinical trial,... Mehr lesen zu: OncoGenex Announces Plans for the Initiation of the Spruce' Clinical Trial Evaluating OGX-427 in Combination with Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer | ||||
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|---|---|---|
| INCYTE | 16,943 | -4,81 % | Incyte Corporation CEO Presents at UBS Global Healthcare Conference (Transcript) |
| ISIS PHARMACEUTICALS | 15,459 | -1,84 % | Isis Pharmaceuticals to Present at the Deutsche Bank 38th Annual dbAccess Health Care Conference |
| TITAN PHARMACEUTICALS | 0,377 | -23,06 % | Titan Pharmaceuticals Announces First Quarter 2013 Financial Results / Titan Management Team to Host Conference Call May 16 at 1:00 p.m. ET / 10:00 a.m. PT |
| PACIRA PHARMACEUTICALS | 22,209 | +1,46 % | Pacira Pharmaceuticals' CEO Discusses Q1 2013 Results - Earnings Call Transcript |
| SYNTHETIC BIOLOGICS | 1,073 | -0,56 % | Synthetic Biologics to Present at the 2nd Annual Marcum LLP MicroCap Conference |
